|1.||Maraskovsky, Eugene: 7 articles (03/2015 - 04/2004)|
|2.||Cebon, Jonathan: 5 articles (03/2009 - 04/2004)|
|3.||Drane, Debbie: 4 articles (01/2013 - 09/2004)|
|4.||Chen, Weisan: 4 articles (03/2009 - 04/2004)|
|5.||Pearse, Martin J: 3 articles (01/2012 - 04/2004)|
|6.||Edwards, Stirling J: 3 articles (01/2012 - 09/2004)|
|7.||Dimopoulos, Nektaria: 3 articles (03/2009 - 06/2004)|
|8.||Davis, Ian D: 3 articles (03/2009 - 06/2004)|
|9.||Pan, Linda: 2 articles (03/2015 - 03/2009)|
|10.||Cebon, Jonathan S: 2 articles (03/2015 - 07/2011)|
04/15/2004 - "NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors."
03/01/2015 - "ISCOMATRIX adjuvant (ISCOMATRIX) is able to induce both tumor Ag-specific cellular and Ab responses to protect mice against tumor challenge, but this is insufficient to result in regression of established solid tumors. "
03/01/2015 - "The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo."
06/22/2004 - "We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with ISCOMATRIX adjuvant and injected into patients intramuscularly. "
03/15/2009 - "Our results point to a tumor-induced systemic immune suppression, showing a clear association between the stage of melanoma progression, the number of Treg in the blood, and the clinical and immunologic efficacy of the NY-ESO-1 ISCOMATRIX cancer vaccine."
|2.||Melanoma (Melanoma, Malignant)
03/15/2015 - "NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus."
03/15/2009 - "We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell-mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma. "
03/15/2009 - "Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma."
02/01/2009 - "Interestingly, HLA-B7(+) melanoma patients who did not receive the NY-ESO-1 ISCOMATRIX vaccine rarely generated a spontaneous T-cell response to this cryptic epitope, suggesting a lack of priming of such T cells in the natural anti-NY-ESO-1 response, which may be corrected by vaccination. "
02/01/2009 - "This bulged epitope was not an impediment to T-cell recognition, however, because four of six HLA-B7(+) melanoma patients vaccinated with NY-ESO-1 ISCOMATRIX vaccine generated a potent T-cell response to this determinant. "
03/03/2015 - "The adjuvant used in the formulation was ISCOMATRIX (IMX), which was found to be effective and safe in human clinical trials of vaccines designed to control other intracellular infections. "
08/01/2009 - "Ferrets vaccinated with the single-injection Iscomatrix vaccines showed fewer clinical manifestations of infection than those given AlPO4 vaccines and remained highly active. "
|4.||Prostatic Neoplasms (Prostate Cancer)
|5.||Human Influenza (Influenza)
01/01/2012 - "Pulmonary delivery of an influenza Iscomatrix vaccine induces a long-lived influenza virus-specific antibody and memory response of suitable length for annual vaccination against influenza."
01/01/2012 - "Sheep were vaccinated in the deep lung with an influenza Iscomatrix vaccine, and serum and lung antibody levels were quantified for up to 1 year. "
01/01/2012 - "Pulmonary delivery of an influenza Iscomatrix adjuvant vaccine induces a strong systemic and mucosal antibody response. "
01/01/2012 - "Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine."
03/19/2010 - "Deep pulmonary delivery of an influenza ISCOMATRIX vaccine has previously been shown to induce a combined mucosal and systemic antibody response. "
|10.||Proteins (Proteins, Gene)